Objective: To investigate the diagnostic value of CA153 and CA125 combined examination in breast cancer patients.Methods: selecting the first people's hospital of Zhengzhou city in April 2018 to April 2019 accepts...Objective: To investigate the diagnostic value of CA153 and CA125 combined examination in breast cancer patients.Methods: selecting the first people's hospital of Zhengzhou city in April 2018 to April 2019 accepts 60 cases of breast cancerpatients as observation group, at the same time to choose healthy check-up women 60 cases as control group, two groups of all tocarry out the tumor markers CA153, CA125 joint inspection, summarizes the tumor markers CA153, CA125 joint inspection in thesensitivity of diagnosis of breast cancer. Results: There were statistically significant differences in the positive rates of tumor markerCA153 and CA125 combined detection between the two groups (P < 0.05), and the higher the stage of breast adenocarcinoma, thehigher the levels of tumor marker CA153 and CA125. Conclusion: Combined examination of tumor markers CA153 and CA125can reduce the incidence of clinical misdiagnosis of breast cancer.展开更多
Objective： To investigate the clinical symptom, ultrasonographic scan finding, serum CA125 value, histopathological type and treatment of small ovarian tumor （〈5 cm） in postmenopausal women. Methods： Retrospectiv...Objective： To investigate the clinical symptom, ultrasonographic scan finding, serum CA125 value, histopathological type and treatment of small ovarian tumor （〈5 cm） in postmenopausal women. Methods： Retrospective analysis was carried out for 52 clinical materials of ovarian tumor cases in women more than one year after menopausal between Jan 1997 and Dec 2004. The largest diameter of the ovarian mass is less than 5 cm. Results： There were 11 ovarian cancers and 1 borderline ovarian tumor among 52 small ovarian tumors （23.1%）. 10 ovarian cancers were epithelial neoplasms and 2 were sex cord-stromal tumors, and 8 cases were in late stage according to FIGO staging system （33.3%）. Compared with benign tumor, there is no significant difference in the onset age, interval after menopausal and duration of history. The main clinical feature is abdominal symptoms, such as abdominal pain and distension in the malignant cases. The patients with benign tumors often showed the ovarian mass during the annual screening or admitted into hospital for other causes. The ultrasonography finding and serum CA125 level showed much difference between benign and malignant cases. Unilocular smooth-walled ovarian cysts mostly were found in benign tumor and the CA125 values were always less than 35 U/ml; but the solid or complex sonographic structures （multilocular, or with a papillary projections on the wall） often indicated a high risk of cancer, especially there was ascites in the pelvic cavity. Serum CA125 level in many cancer cases was elevated （〉35 U/ml）, over 300 U/ml in more than half of the patients. Surgery is still the first choice to treat ovarian cancer, and chemotherapy would be an auxiliary method. Till now, 3 ovarian cancer patients died of complications of cancer and 2 cases had recurrence. Conclusion： Small ovarian tumor in postmenopausal women has a comparatively low malignant occurrence but more in later stage. Many are epithelial carcinoma. If there is complex or parenchymal sonographic structure accompanied with a high serum CA125 level, operation should be considered, while it can be followed up when the ultrasound shows a smooth cyst with normal CA125 value.展开更多
Objectives and Methods: A modified radioimmunoassay (RIA) of serum inhibin (INH) was developed and applied to measure serum INH contents in 39 fertile and 16 postmenopausal women. Thirty-three cases of ovarian tumors,...Objectives and Methods: A modified radioimmunoassay (RIA) of serum inhibin (INH) was developed and applied to measure serum INH contents in 39 fertile and 16 postmenopausal women. Thirty-three cases of ovarian tumors, including granulosa cell tumors and other kinds of ovarian tumors, were monitored by serum INH RIA. Results: The mean value of serum INH contents in follicular, peri-ovulatory and mid-luteal phases of fertile women were 9.48±7.10 pg/ml (2.04～18.53pg/ml), 19.04±9.73 pg/ml (3.49～33.26 pg/ml) and 131.13±110.81 pg/ml (3.49～ 341.10 pg/ml), respectively. Serum INH concentration was negatively correlated with serum FSH concentration, (rs=?0.483,P<0.01). Serum IHN contents were less than 3.6 pg/ml in normal postmenopausal women. The mean value of serum INH contents in ovarian granulosa cell tumor, thecoma, mucinous cystadenocarcinoma and malignant teratoma cases were significantly higher than that of other ovarian tumors, (P<0.01). Serum INH contents were elevated in ovarian granulosa cell tumor, thecoma, mucinous cystadenocaricinoma and endometrioid carcinoma cases with serum CA-125 values in normal range before operation, but serum INH contents decreased to normal range within one week after operation. And consecutive serum INH RIA could be a valuable tool in monitoring for therapeutic effect. Conclusion: Modified INH RIA was of convenient, time-saving and quantitative characteristics, especially with its high sensitivity (<1 pg/ml). There was a regular change of serum INH concentrations during menstrual cycle. INH could inhibit the synthesis and secretion of follicle stimulating hormone (FSH). INH would become a valuable marker for ovarian tumor. INH RIA combined with the measurement of serum CA-125 would be helpful to the early diagnosis, treatment and follow-up for ovarian cancer.展开更多
目的探讨贝伐珠单抗靶向治疗卵巢癌对肿瘤标志物的影响。方法选取2019年1月—2021年12月福建医科大学附属福州市第一医院收治的80例卵巢癌患者,根据不同治疗药物进行分组,分别纳入单独行化疗的化疗组和行贝伐珠单抗靶向治疗的靶向组,每...目的探讨贝伐珠单抗靶向治疗卵巢癌对肿瘤标志物的影响。方法选取2019年1月—2021年12月福建医科大学附属福州市第一医院收治的80例卵巢癌患者,根据不同治疗药物进行分组,分别纳入单独行化疗的化疗组和行贝伐珠单抗靶向治疗的靶向组,每组40例。测评2组治疗前后肿瘤标志物蛋白芯片中糖链抗原125(glycoantigens in protein chips-125,CA-125)、人附睾蛋白4(Human epididymal protein 4,HE4)水平及血管内皮生长因子(vascular endothelial growth factor,VEGF)水平,治疗后客观缓解率、疾病控制率、免疫指标、癌症患者生命质量测定量表(quality of life scale for cancer patients,FACT-G)和抑郁自评量表(self-rating depression scale,SDS)、焦虑自评量表(self-rating anxiety scale,SAS)评分。结果治疗后,靶向组治疗客观缓解率为65.00%,疾病控制率为87.50%,高于化疗组的42.50%、70.00%(P<0.05);靶向组CA-125、HE4、VEGF指标低于化疗组,CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于化疗组,FACT-G评分高于化疗组,而SDS、SAS评分低于化疗组,差异有统计学意义(P<0.05)。结论贝伐珠单抗靶向治疗卵巢癌患者可抑制肿瘤新生血管形成和生长,增强治疗效果,改善患者的心理情绪和生活质量。展开更多
文摘Objective: To investigate the diagnostic value of CA153 and CA125 combined examination in breast cancer patients.Methods: selecting the first people's hospital of Zhengzhou city in April 2018 to April 2019 accepts 60 cases of breast cancerpatients as observation group, at the same time to choose healthy check-up women 60 cases as control group, two groups of all tocarry out the tumor markers CA153, CA125 joint inspection, summarizes the tumor markers CA153, CA125 joint inspection in thesensitivity of diagnosis of breast cancer. Results: There were statistically significant differences in the positive rates of tumor markerCA153 and CA125 combined detection between the two groups (P < 0.05), and the higher the stage of breast adenocarcinoma, thehigher the levels of tumor marker CA153 and CA125. Conclusion: Combined examination of tumor markers CA153 and CA125can reduce the incidence of clinical misdiagnosis of breast cancer.
文摘Objective： To investigate the clinical symptom, ultrasonographic scan finding, serum CA125 value, histopathological type and treatment of small ovarian tumor （〈5 cm） in postmenopausal women. Methods： Retrospective analysis was carried out for 52 clinical materials of ovarian tumor cases in women more than one year after menopausal between Jan 1997 and Dec 2004. The largest diameter of the ovarian mass is less than 5 cm. Results： There were 11 ovarian cancers and 1 borderline ovarian tumor among 52 small ovarian tumors （23.1%）. 10 ovarian cancers were epithelial neoplasms and 2 were sex cord-stromal tumors, and 8 cases were in late stage according to FIGO staging system （33.3%）. Compared with benign tumor, there is no significant difference in the onset age, interval after menopausal and duration of history. The main clinical feature is abdominal symptoms, such as abdominal pain and distension in the malignant cases. The patients with benign tumors often showed the ovarian mass during the annual screening or admitted into hospital for other causes. The ultrasonography finding and serum CA125 level showed much difference between benign and malignant cases. Unilocular smooth-walled ovarian cysts mostly were found in benign tumor and the CA125 values were always less than 35 U/ml; but the solid or complex sonographic structures （multilocular, or with a papillary projections on the wall） often indicated a high risk of cancer, especially there was ascites in the pelvic cavity. Serum CA125 level in many cancer cases was elevated （〉35 U/ml）, over 300 U/ml in more than half of the patients. Surgery is still the first choice to treat ovarian cancer, and chemotherapy would be an auxiliary method. Till now, 3 ovarian cancer patients died of complications of cancer and 2 cases had recurrence. Conclusion： Small ovarian tumor in postmenopausal women has a comparatively low malignant occurrence but more in later stage. Many are epithelial carcinoma. If there is complex or parenchymal sonographic structure accompanied with a high serum CA125 level, operation should be considered, while it can be followed up when the ultrasound shows a smooth cyst with normal CA125 value.
文摘Objectives and Methods: A modified radioimmunoassay (RIA) of serum inhibin (INH) was developed and applied to measure serum INH contents in 39 fertile and 16 postmenopausal women. Thirty-three cases of ovarian tumors, including granulosa cell tumors and other kinds of ovarian tumors, were monitored by serum INH RIA. Results: The mean value of serum INH contents in follicular, peri-ovulatory and mid-luteal phases of fertile women were 9.48±7.10 pg/ml (2.04～18.53pg/ml), 19.04±9.73 pg/ml (3.49～33.26 pg/ml) and 131.13±110.81 pg/ml (3.49～ 341.10 pg/ml), respectively. Serum INH concentration was negatively correlated with serum FSH concentration, (rs=?0.483,P<0.01). Serum IHN contents were less than 3.6 pg/ml in normal postmenopausal women. The mean value of serum INH contents in ovarian granulosa cell tumor, thecoma, mucinous cystadenocarcinoma and malignant teratoma cases were significantly higher than that of other ovarian tumors, (P<0.01). Serum INH contents were elevated in ovarian granulosa cell tumor, thecoma, mucinous cystadenocaricinoma and endometrioid carcinoma cases with serum CA-125 values in normal range before operation, but serum INH contents decreased to normal range within one week after operation. And consecutive serum INH RIA could be a valuable tool in monitoring for therapeutic effect. Conclusion: Modified INH RIA was of convenient, time-saving and quantitative characteristics, especially with its high sensitivity (<1 pg/ml). There was a regular change of serum INH concentrations during menstrual cycle. INH could inhibit the synthesis and secretion of follicle stimulating hormone (FSH). INH would become a valuable marker for ovarian tumor. INH RIA combined with the measurement of serum CA-125 would be helpful to the early diagnosis, treatment and follow-up for ovarian cancer.
文摘目的探讨贝伐珠单抗靶向治疗卵巢癌对肿瘤标志物的影响。方法选取2019年1月—2021年12月福建医科大学附属福州市第一医院收治的80例卵巢癌患者,根据不同治疗药物进行分组,分别纳入单独行化疗的化疗组和行贝伐珠单抗靶向治疗的靶向组,每组40例。测评2组治疗前后肿瘤标志物蛋白芯片中糖链抗原125(glycoantigens in protein chips-125,CA-125)、人附睾蛋白4(Human epididymal protein 4,HE4)水平及血管内皮生长因子(vascular endothelial growth factor,VEGF)水平,治疗后客观缓解率、疾病控制率、免疫指标、癌症患者生命质量测定量表(quality of life scale for cancer patients,FACT-G)和抑郁自评量表(self-rating depression scale,SDS)、焦虑自评量表(self-rating anxiety scale,SAS)评分。结果治疗后,靶向组治疗客观缓解率为65.00%,疾病控制率为87.50%,高于化疗组的42.50%、70.00%(P<0.05);靶向组CA-125、HE4、VEGF指标低于化疗组,CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于化疗组,FACT-G评分高于化疗组,而SDS、SAS评分低于化疗组,差异有统计学意义(P<0.05)。结论贝伐珠单抗靶向治疗卵巢癌患者可抑制肿瘤新生血管形成和生长,增强治疗效果,改善患者的心理情绪和生活质量。
